Skip to main content



Full Schedule

Full Schedule

  • Saturday, September 13, 2025
  • 07:15 - 08:15 CEST
    Coffee & Tea
  • 08:15 - 08:25 CEST
    Welcome and Introductions
    Chair: Tadeusz Robak, MD, PhD – Department of Hematology, Medical University of Lodz; Department of General Hematology and Internal Medicine, Copernicus Memorial Hospital
    Speaker: Iwona Hus, MD, PhD – National Medical Institute of the Ministry of the Interior and Administration
  • 08:25 - 08:40 CEST
    Current Status and the Future of iwCLL
    Speaker: Thomas J. Kipps, MD, PhD – UC San Diego, Moores Cancer Center
  • 08:40 - 10:15 CEST
    Session 1: Novel Insights Into the Pathogenesis of CLL
    Co-Chair: Catherine Wu, MD – Dana-Farber Cancer Institute, Harvard Medical School
    Co-Chair: Stephan Stilgenbauer, MD – Division of CLL, Internal Medicine III, Ulm University
  • 10:15 - 10:35 CEST
    Morning Break
  • 10:35 - 12:20 CEST
    Session 2: Genomics, Epigenetics, and Proteomics of CLL
    Co-Chair: Thorsten Zenz, MD – University of Zurich
    Co-Chair: Sarka Pospisilova, PhD – Masaryk University and University Hospital Brno
  • 12:20 - 12:50 CEST
    Lunch
  • 12:50 - 13:50 CEST
    Industry Supported Symposium Platinum Sponsor
  • 12:50 - 13:50 CEST
    Industry Supported Symposium: From Data to Clinical Decisions: Selecting the Optimal FDT for 1L CLL Patients
  • 13:55 - 15:20 CEST
    Session 3: Immunology and the Tumor Microenvironment
    Co-Chair: Nicholas Chiorazzi, MD – The Feinstein Institutes for Medical Research, Northwell Health System
    Co-Chair: Martina Seiffert, PhD – German Cancer Research Center
  • 15:20 - 15:40 CEST
    Afternoon Break
  • 15:40 - 17:10 CEST
    Session 4: Preclinical Studies of Novel Therapies
    Co-Chair: Paolo Ghia, MD, PhD – Università Vita Salute and IRCCS Ospedale San Raffaele
    Co-Chair: Shih-Shih Chen, PhD – The Feinstein Institutes for Medical Research
  • 17:30 - 18:30 CEST
    Industry Supported Symposium: Advances and Challenges in Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL) Management